tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

MiNK Therapeutics downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar downgraded MiNK Therapeutics (INKT) to Neutral from Buy with a $35 price target

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1